Floatz Rating
B62/100
Confidence
Indicative
Sponsor
University Health Network, Toronto
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04492553CT.gov Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality | — | Completed | — | — | — |
NCT00467987CT.gov Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism | — | Terminated | — | — | — |
NCT00351819CT.gov Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hypogonadotropic Hypogonadism
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tamoxifen (this asset) | University Health Network, Toronto | P2 | B · 62 |
| Testosterone Undecylate | Canisius-Wilhelmina Hospital | P4 | A |
| Metformin | University Medical Centre Ljubljana | P4 | BBB |
| Anastrozole | Baylor College of Medicine | P4 | BBB |
| Liraglutide | University Medical Centre Ljubljana | P4 | BB |
| Testim | Odense University Hospital | P4 | BB |
| Androxal | Repros Therapeutics Inc. | P3 | BB |
| Anakinra | University Hospital, Basel, Switzerland | P3 | BB |
| Letrozole | Rijnstate Hospital | P3 | BB |
+14 more in the Hypogonadotropic Hypogonadism cohort
Other indications for Tamoxifen
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 75 |
| Invasive Breast Carcinoma | — | P4 | BBB · 75 |
| Breast Fibroadenoma | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tamoxifen in Hypogonadotropic Hypogonadism. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tamoxifen-hypogonadotropic-hypogonadism
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →